publication date: Jul. 10, 2015

Do-It-Yourself Guide to ODAC

Circle One: Yes, No, Maybe


FDA has often asked ODAC members to discuss broad scientific questions. However, the approval questions have, without an exception, been shoehorned into the up-or-down dichotomy.

What is ODAC without a vote on approval questions?

Here, The Cancer Letter has combined a transcript of the ODAC discussion with a coding scale that may provide a clue about how the vote on necitumumab would have gone.


Grzegorz Nowakowski, assistant professor of medicine, Mayo Clinic Rochester:

I think this is a well-conducted study, which provides a small but significant benefit in terms of overall survival, which is the endpoint, which captures both safety and efficacy of this combination. The toxicity is acceptable, considering the severity of the disease.

I think there are concerns about the supportive care, which we alluded to, about replacement of magnesium, and thromboembolism prophylaxis, but overall I believe that the risk-benefit ratio appears to be pointing towards the benefit of this combination.


Code this answer (circle one):    Yes    No    Maybe


Michael Menefee, assistant professor, Division of Hematology and … Continue reading 41-27 Do-It-Yourself Guide to ODAC Circle One: Yes, No, Maybe

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.